The efficacy of CT -guided radioactive 125I seed implantation for retroperitoneal lymph node metastases：preliminary evaluation of 18 cases
10.3969/j.issn.1008-794X.2015.03.009
- VernacularTitle:CT引导下125I粒子植入治疗腹膜后淋巴结转移癌18例的初步疗效
- Author:
Juan WANG
;
Juan WU
;
Dong WEI
;
Aixia SUI
;
Xiaolu YAN
;
Jing ZHAO
;
Hongtao ZHANG
;
Zeyang WANG
- Publication Type:Journal Article
- Keywords:
retroperitoneal lymph node metastasis;
125I seed implantation;
brachytherapy
- From:
Journal of Interventional Radiology
2015;(3):219-222
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of CT-Guided radioactive 125I seed implantation in treating retroperitoneal lymph node metastases. Methods Eighteen patients with retroperitoneal lymph node metastases (20 lesions in total) received CT-guided radioactive 125I seed implantation. Treatment planning system (TPS) was used to formulate the therapeutic protocol. The radioactive activity of 125I particle ranged from 1.11 × 107-2.96 × 107 Bq (0.3-0.8 mCi) and the matched peripheral dose (MPD) was 60 -100 Gy. Postoperative dosimetry was routinely performed for all the patients in one week. Postoperative D90 (90%dose received by target volume) was 53 -107 Gy. The patient’s clinical benefit response (CBR), two-month local tumor control rate and one-year survival rate were evaluated, and the complications were recorded. Results All the patients were followed up for 2 -15 months with a median time of 5 months. The one-year survival rate was 22.2%. The clinical benefit rate, overall effective rate and two-month local tumor control rate were 72.2%, 70.0% and 90.0% respectively. No serious complications occurred in all patients. Conclusion For the treatment of retroperitoneal lymph node metastases, CT-guided radioactive 125I seed implantation is mini-invasive with satisfactory short-term effect and fewer complications. Therefore, this technique is a relatively safe therapeutic means.
